Our Pricing

Understanding Wegovy BMI Eligibility in the UK

Published on: June 03, 2026

Understanding wegovy bmi eligibility uk criteria is essential before starting treatment. At Cured Pharmacy, our UK-registered clinical team assesses your eligibility during a free 3-minute consultation, with transparent pricing from £79.00 for patients who qualify. Wegovy (semaglutide) is a prescription-only medication licensed by the MHRA for weight management in adults meeting specific clinical criteria.

Wegovy BMI Eligibility Criteria in the UK

The MHRA and NICE guidelines specify that Wegovy is licensed for adults with a body mass index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. These thresholds reflect the clinical evidence from the STEP trial programme, which demonstrated significant weight reduction in patients meeting these criteria.

For individuals of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background, the BMI thresholds are adjusted downward by 2.5 kg/m² to account for differences in body composition and metabolic risk profiles [2]. This means eligibility begins at BMI 27.5 kg/m² without comorbidities, or BMI 25 kg/m² with weight-related health conditions.

During your online consultation at Cured Pharmacy, our UK prescribers calculate your BMI using your height and weight, review your medical history for contraindications, and assess whether Wegovy is clinically appropriate for your circumstances. All assessments are conducted by GPhC-registered professionals, with superintendent pharmacist Tarun Kumar (GPhC 2233073) overseeing clinical governance.

Weight-Related Comorbidities That Support Eligibility

Weight-related comorbidities that may support Wegovy eligibility at the lower BMI threshold include prediabetes, type 2 diabetes mellitus, hypertension, dyslipidaemia, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, and obstructive sleep apnoea. Your prescriber will review your medical records and current medications to determine if these conditions are present and adequately documented.

How Wegovy Works for Weight Management

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism [3]. By activating GLP-1 receptors in the brain, Wegovy reduces hunger signals, increases feelings of fullness after meals, and slows gastric emptying, leading to reduced caloric intake.

In the landmark STEP 1 trial, participants receiving once-weekly semaglutide 2.4 mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [3]. Importantly, 86.4% of participants in the semaglutide group lost at least 5% of their baseline body weight, and 69.1% achieved at least 10% weight loss—outcomes that significantly exceed those seen with lifestyle interventions alone.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen device. Treatment begins with a low dose of 0.25 mg weekly, gradually escalating over 16 weeks to the maintenance dose of 2.4 mg to minimise gastrointestinal side effects. This dose escalation schedule is supported by clinical trial data showing improved tolerability compared to rapid titration [4].

Wegovy Pricing at Cured Pharmacy

Cured Pharmacy offers Wegovy at competitive UK pricing, starting from £79.00 per pen. This transparent upfront pricing includes your medication, free online consultation with a UK prescriber, and discreet delivery to your address. Unlike some providers, we display prices before you begin your assessment, ensuring no hidden costs or unexpected charges.

The exact cost depends on your prescribed dose, which progresses from the 0.25 mg starter dose through to the 2.4 mg maintenance dose. Your prescriber will determine the appropriate dosing schedule based on your response to treatment and tolerability. We guarantee the lowest prices in the UK for genuine, MHRA-licensed Wegovy pens sourced through regulated pharmaceutical supply chains.

All Wegovy prescriptions at Cured Pharmacy are issued following clinical assessment by our UK-registered prescribers. You'll complete a brief medical questionnaire covering your weight history, current medications, and relevant health conditions. Most consultations are reviewed within hours, and approved prescriptions are dispensed by our GPhC-registered pharmacy (9012511) for next-day delivery across the UK.

Payment Options and Subscription Plans

We accept all major credit and debit cards, with secure payment processing and full data encryption. For patients on long-term treatment, we offer flexible subscription options that ensure continuous supply without the need to reorder manually each month. You can pause, adjust, or cancel your subscription at any time through your online account.

Wegovy vs Other Weight Loss Treatments

Wegovy is one of several prescription weight loss medications available through UK pharmacies, each with distinct mechanisms, dosing schedules, and clinical evidence. Understanding these differences helps patients and prescribers select the most appropriate treatment based on individual circumstances, preferences, and clinical goals.

Saxenda (liraglutide) is another GLP-1 receptor agonist licensed for weight management, but requires daily subcutaneous injections at a maximum dose of 3.0 mg. While effective, clinical trials show Saxenda produces less weight loss on average than Wegovy—approximately 8% body weight reduction in the SCALE trial compared to Wegovy's 14.9% in STEP 1 [3][5]. The daily injection schedule may be less convenient for some patients, though others prefer the flexibility of adjusting doses day-to-day.

Orlistat and Mysimba represent non-injectable alternatives. Orlistat works by blocking fat absorption in the intestine, leading to modest weight loss of 3-5% when combined with a reduced-calorie diet [6]. Mysimba combines naltrexone and bupropion to reduce appetite and cravings through central nervous system pathways. Both oral medications may suit patients who prefer not to use injections, though their efficacy is generally lower than GLP-1 receptor agonists in head-to-head comparisons.

Common Side Effects and Safety Considerations

The most frequently reported side effects of Wegovy are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal pain [3]. These symptoms are typically mild to moderate in severity and diminish over time as the body adjusts to treatment. The gradual dose escalation schedule is specifically designed to minimise these effects—starting at 0.25 mg weekly and increasing slowly over 16 weeks.

Serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other glucose-lowering medications). Wegovy carries a boxed warning in some jurisdictions regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [4]. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

During your consultation, our UK prescribers review your full medical history to identify contraindications, including pregnancy, breastfeeding, severe gastrointestinal disease, and previous allergic reactions to semaglutide. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis while taking Wegovy, you should stop treatment immediately and contact your healthcare provider.

Monitoring and Follow-Up Care

Effective weight management with Wegovy requires ongoing monitoring of your progress, side effects, and overall health. At Cured Pharmacy, we recommend follow-up consultations every 12 weeks to assess weight loss, review tolerability, and adjust treatment as needed. Your prescriber may request blood tests to monitor kidney function, liver enzymes, and lipid profiles, particularly if you have pre-existing metabolic conditions.

Starting Your Wegovy Treatment Journey

Beginning Wegovy treatment at Cured Pharmacy is straightforward and designed for convenience. Start by completing our free online consultation, which takes under 3 minutes and covers your medical history, current medications, weight loss goals, and eligibility criteria. Our UK-registered prescribers review your submission, typically within a few hours during business days.

If approved, your prescription is sent electronically to our GPhC-registered pharmacy (9012511), where we dispense genuine UK-licensed Wegovy pens. All medications are packaged discreetly with no external branding, and dispatched via tracked courier for next-day delivery across the UK. You'll receive injection technique guidance, dose escalation schedules, and information on managing potential side effects.

Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating the 14.9% average weight loss included lifestyle intervention programmes alongside medication [3]. Our clinical team can provide evidence-based guidance on dietary modifications and activity levels appropriate for your circumstances, though we recommend working with your GP or a registered dietitian for comprehensive weight management support.

Eligibility Assessment and Prescriber Approval

Not all patients who request Wegovy will be suitable candidates. Our prescribers must be satisfied that you meet MHRA-approved eligibility criteria, have no contraindications, and understand the commitment required for long-term treatment. If Wegovy is not appropriate for you, we'll explain why and discuss alternative options that may better suit your clinical profile and goals.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen. MHRA. [accessed 13 August 2026]
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Sjöström, L., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults meeting specific BMI and clinical criteria. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and lifestyle changes.